What is the recommended management of a Pseudomonas aeruginosa urinary tract infection in a male patient?

Management of Pseudomonas aeruginosa UTI in Men

All urinary tract infections in men are classified as complicated UTIs and should be treated with targeted antimicrobial therapy for 7-14 days (14 days when prostatitis cannot be excluded), guided by culture and susceptibility testing. 1

Key Classification Principle

• UTI in males is automatically considered complicated regardless of other factors, according to the 2024 European Association of Urology guidelines. 1
• Pseudomonas aeruginosa is specifically listed among the common pathogens in complicated UTIs, alongside E. coli, Proteus, Klebsiella, Serratia, and Enterococcus species. 1
• Antimicrobial resistance is more likely in complicated UTIs compared to uncomplicated infections. 1

Initial Management Steps

Obtain Culture and Susceptibility Testing

• Urine culture with antimicrobial susceptibility testing is mandatory before initiating therapy. 1
• This is critical because Pseudomonas aeruginosa has high potential for multidrug resistance and can develop resistance during ongoing treatment. 2, 3, 4

Assess for Urological Abnormalities

• Appropriate management of any underlying urological abnormality is mandatory. 1
• Look specifically for: urinary obstruction, foreign bodies (catheters), incomplete voiding, vesicoureteral reflux, recent instrumentation, or structural abnormalities. 1
• In febrile patients with MDR Pseudomonas aeruginosa UTI and urinary obstruction, drainage of the obstructed urinary tract is strongly recommended and may be sufficient even when the organism shows resistance to all antimicrobials. 5

Empirical Antibiotic Selection

For Severe Infections or Hospitalized Patients

Initiate intravenous therapy with one of the following based on local resistance patterns: 1

First-line options for Pseudomonas coverage:

• Ceftazidime-avibactam 2.5 g IV three times daily 1
• Ceftolozane-tazobactam 1.5 g IV three times daily 1, 6
• Cefepime 1-2 g IV twice daily (higher dose recommended) 1
• Piperacillin-tazobactam 2.5-4.5 g IV three times daily 1

Alternative options:

• Aminoglycosides: Gentamicin 5 mg/kg IV once daily or Amikacin 15 mg/kg IV once daily 1
• Fluoroquinolones: Ciprofloxacin 400 mg IV twice daily or Levofloxacin 750 mg IV once daily (only if local resistance <10%) 1

For Multidrug-Resistant or Extensively Drug-Resistant Strains

Reserve these agents for confirmed MDR/XDR Pseudomonas based on early culture results: 1

• Cefiderocol 2 g IV three times daily 1, 3
• Imipenem-cilastatin-relebactam 6, 3
• Meropenem 1 g IV three times daily (only for confirmed susceptibility) 1

For Non-Severe Outpatient Cases

Oral fluoroquinolones may be considered if the organism is susceptible and local resistance is <10%: 1

• Ciprofloxacin 500-750 mg orally twice daily 1, 7
• Levofloxacin 750 mg orally once daily 1

Tailoring Therapy Based on Susceptibility Results

When Susceptibility Results Return

• De-escalate to the narrowest spectrum agent with documented in vitro activity. 1
• Switch from IV to oral therapy when the patient is hemodynamically stable and afebrile for at least 48 hours. 1
• For patients with difficult-to-treat resistant Pseudomonas aeruginosa, ceftolozane-tazobactam is suggested if active in vitro. 6

Combination Therapy Considerations

• For severe infections caused by Pseudomonas susceptible only to polymyxins, aminoglycosides, or fosfomycin, treatment with two in vitro active drugs is suggested. 6
• For patients with infections susceptible to and treated with ceftazidime-avibactam, ceftolozane-tazobactam, or cefiderocol, combination therapy is NOT recommended. 6
• Lacking evidence, no recommendation can be made for or against combination therapy with new beta-lactam/beta-lactamase inhibitors for carbapenem-resistant Pseudomonas aeruginosa. 6

Treatment Duration

The standard duration is 7-14 days: 1

• Use 14 days when prostatitis cannot be excluded (which is common in men with UTI). 1
• Consider 7 days when the patient is hemodynamically stable, afebrile for at least 48 hours, and there are relative contraindications to prolonged antibiotic use. 1
• Duration should be closely related to treatment of any underlying urological abnormality. 1

Critical Pitfalls to Avoid

Antibiotic Selection Errors

• Avoid nitrofurantoin, oral fosfomycin, and pivmecillinam as there are insufficient data regarding their efficacy for complicated UTIs. 1
• Do not use trimethoprim-sulfamethoxazole empirically for Pseudomonas aeruginosa as it is not reliably active against this organism. 1
• Reserve carbapenems and novel broad-spectrum agents only for patients with early culture results indicating multidrug-resistant organisms to preserve these agents. 1

Resistance Development

• Monitor for emergence of resistance during therapy, particularly with fluoroquinolones where resistance can develop in up to 30% of Pseudomonas aeruginosa treatment failures. 7
• Pseudomonas aeruginosa has a large genome with high potential for genetic mutations enabling multidrug resistance development. 3, 4

Catheter-Associated Infections

• If a urinary catheter is present, this is a catheter-associated UTI (CAUTI) which carries approximately 10% mortality when associated with bacteremia. 1
• Catheterization duration is the most important risk factor for CAUTI development, with bacteriuria incidence of 3-8% per day. 1, 8

Inadequate Source Control

• Failure to address urinary obstruction is a critical error that can lead to treatment failure even with appropriate antibiotics. 5
• In patients with urinary obstruction and MDR Pseudomonas, urinary drainage may be more important than antibiotic selection. 5